Cancer Immunotherapy, Immune Checkpoint Blockade And Predictive Biomarkers | 104322
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
A notorious question in immunology has been whether an immune response could also be raised against cancer cells.
Researchers have indeed, for a long time, studied if cancer prevention could be a primary function of the immune system.
Based on current research, it is clear that the immune system can recognize and eliminate transformed cells. A growing number
of studies have investigated the immune system of cancer patients and how it is prone to immunosuppression, due in part to the
decrease of lymphocyte proliferation and cytotoxic activity. In solid tumors, one of the reasons for this phenotype is attributed
to the immunoedition, tumor microenviroment, immune privilege and the expression of the negative immune checkpoints
which lead to an insufficient T cell activity and consequently cancer progression. After the approval of immune checkpoint
blockade anti-CTLA-4 and anti-PD-1 several costimulatory and coinhibitory molecules have been studied exhaustively. The
immune monitoring studies have supported the hypothesis that combining immunotherapy and standard treatment or their
use as monotherapy, can benefit patients developing several types of cancer; by analyzing their ligands, infiltration quality,
co-stimulatory/inhibitory profile and microenviroment. Several assays such whole exome sequencing (WES), protein array,
flow/mass cytometry (CyTOF), multicolor immunohistochemistry (IHC), Multiplexed Ion Beam Imaging (MIBI), Systematic
evolution of ligands by exponential enrichment (SELEX), epigenetic modification and B/T cell receptor repertoire sequencing
have been used to pursue potential biomarkers and contribute for the future of cancer immunotherapy. My talk will discusses
the recent findings on immune checkpoint function and the use of checkpoint blockade on cancer immunotherapy.
Jorge Augusto Borin Scutti has completed his Master and PhD at Federal University of São Paulo (UNIFESP) and Post-doctoral studies from MD Anderson Cancer Center (MDACC). Currently, he is working as a Senior Research Scientist at Immunotherapy Platform (IMT) at MD Anderson Cancer Center working on immune monitoring cancer patients under immunotherapy, especially immune checkpoints inhibitors in several clinical trials in numerous types of cancer. He has published several scientific articles and book chapters in reputed journals.